Pacira Pharm Inc (PCRX) Stock Price, Quote & News

Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld c...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 813 553 6680

Website: www.pacira.com

Address:

5401 West Kennedy Boulevard, Suite 890, Tampa, United States

A_Train1 Aug. 15 at 9:13 PM

$PCRX oof … what happened there at the EOD? Just fell off a cliff…ouch!

0 · Reply

Winning_calls Aug. 11 at 2:46 AM

$PCRX pick me up @$25.25

0 · Reply

Doozio Aug. 10 at 6:37 PM

$PCRX or 7/31 was the Thursday 🐑 low. Chop chop huckleberries 🐒🍌🧠⏰♾️

0 · Reply

MuesLee Aug. 5 at 8:25 PM

$PCRX opened position at 22.35 after nice ER and proven continuation of buybacks. :)

1 · Reply

DonCorleone77 Aug. 5 at 8:08 PM

$PCRX Pacira reports Q2 EPS 74c, consensus 71c -- Q2 revenue $181.1M, consensus $182.76M. -- Narrows FY25 revenue view to $730M-$750M from $725M-$765M, consensus $741.72M. -- Raises FY25 gross margin view to 78%-80% from 76%-78%.

0 · Reply

GoldKing23 Jul. 22 at 3:30 PM

$PCRX Pacira BioSciences (NASDAQ: PCRX) has announced a strategic collaboration with Johnson & Johnson MedTech -Strategic partnership with Johnson & Johnson MedTech expands market reach -Access to J&J's specialized sales force for co-promotion -Potential to tap into 7 million annual intra-articular knee injection market -Expansion into additional physician specialties beyond orthopedics

0 · Reply

GoldKing23 Jul. 18 at 3:42 PM

$PCRX Valuation Looks Compressed: PCRX is trading near multi-year lows (~$22), a big drop from its ~$80 highs in 2021. Forward P/E ratio is ~9–10x, well below industry average (15–20x for specialty pharma). Price-to-Sales ratio is ~1x, which is low for a company with consistent revenue. Resilient Core Product (EXPAREL): Still growing (~7% Y/Y in Q1 2025) despite industry headwinds. No generic competition yet and patent protection until 2029-2031. Free Cash Flow Positive: Management expects strong free cash flow for 2025, with lighter capital expenses after recent manufacturing streamlining.

0 · Reply

MissMiner Jul. 15 at 1:35 PM

$PCRX 🔥

0 · Reply

Rage_Against_The_Machine Jun. 18 at 9:34 PM

Pacira's $PCRX ZILRETTA remains the only FDA-approved extended-release OA treatment as osteoarthritis market grows to $19B. With 97M cases globally and their Phase III pipeline advancing, the stock's 7.97 forward P/E looks cheap for a company controlling proprietary pain management IP. Market still pricing in generic risks post-2029? https://www.prnewswire.com/news-releases/osteoarthritis-market-is-predicted-to-exhibit-remarkable-growth-during-the-forecast-period-20252034--delveinsight-302484831.html

0 · Reply

GoldKing23 Jun. 11 at 3:05 PM

$PCRX Based on the one-year price targets offered by 6 analysts, the average target price for Pacira BioSciences Inc (PCRX, Financial) is $41.50 with a high estimate of $65.00

0 · Reply

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:00 PM EDT - 13 days ago

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 8:00 AM EDT - 25 days ago

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

Jul 16, 2025, 8:40 AM EDT - 4 weeks ago

Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit

Jul 3, 2025, 4:01 PM EDT - 6 weeks ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 17, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 2 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out

May 20, 2025, 10:00 AM EDT - 3 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect

May 14, 2025, 8:00 AM EDT - 3 months ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

May 13, 2025, 10:35 AM EDT - 3 months ago

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

May 13, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out

May 11, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

May 8, 2025, 10:31 PM EDT - 3 months ago

Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:00 PM EDT - 3 months ago

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 8, 2025, 10:00 AM EDT - 3 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 6, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect

May 4, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

May 2, 2025, 8:00 AM EDT - 3 months ago

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 1, 2025, 10:00 AM EDT - 3 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation

Apr 29, 2025, 8:00 AM EDT - 3 months ago

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Apr 24, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out

Apr 22, 2025, 4:01 PM EDT - 4 months ago

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

Apr 22, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out

Apr 21, 2025, 8:15 AM EDT - 4 months ago

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Apr 17, 2025, 5:00 PM EDT - 4 months ago

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Apr 9, 2025, 10:03 AM EDT - 4 months ago

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

Apr 8, 2025, 10:45 AM EDT - 4 months ago

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Apr 7, 2025, 4:30 PM EDT - 4 months ago

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 14, 2025, 5:27 PM EDT - 5 months ago

Pacira BioSciences: Back On An Uptrend After Positive Developments

Mar 14, 2025, 4:05 PM EDT - 5 months ago

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

Mar 14, 2025, 8:25 AM EDT - 5 months ago

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

Mar 13, 2025, 10:45 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

A_Train1 Aug. 15 at 9:13 PM

$PCRX oof … what happened there at the EOD? Just fell off a cliff…ouch!

0 · Reply

Winning_calls Aug. 11 at 2:46 AM

$PCRX pick me up @$25.25

0 · Reply

Doozio Aug. 10 at 6:37 PM

$PCRX or 7/31 was the Thursday 🐑 low. Chop chop huckleberries 🐒🍌🧠⏰♾️

0 · Reply

MuesLee Aug. 5 at 8:25 PM

$PCRX opened position at 22.35 after nice ER and proven continuation of buybacks. :)

1 · Reply

DonCorleone77 Aug. 5 at 8:08 PM

0 · Reply

GoldKing23 Jul. 22 at 3:30 PM

0 · Reply

GoldKing23 Jul. 18 at 3:42 PM

0 · Reply

MissMiner Jul. 15 at 1:35 PM

$PCRX 🔥

0 · Reply

Rage_Against_The_Machine Jun. 18 at 9:34 PM

0 · Reply

GoldKing23 Jun. 11 at 3:05 PM

$PCRX Based on the one-year price targets offered by 6 analysts, the average target price for Pacira BioSciences Inc (PCRX, Financial) is $41.50 with a high estimate of $65.00

0 · Reply

GoldKing23 Jun. 11 at 1:01 PM

$PCRX https://finance.yahoo.com/news/pacira-biosciences-unveils-three-clinical-120000142.html

0 · Reply

BiopharmaWatch_com Jun. 9 at 6:19 PM

We’re tracking the biggest biotech catalysts this week on BiopharmaWatch: • Real-time FDA & PDUFA events • POA % and pipeline stage • Price and market cap trends Tickers on our radar: $OKYO $TSHA $MDGL $PCRX $NAMS Who’s on your watchlist? Tag your pick below! #Biotech #Stocks #CatalystWatch #TradingStrategy #Pharma #FDA #PDUFA #ClinicalTrials #BiotechInvesting #BiotechStocks

0 · Reply

MadMaverick Jun. 2 at 1:10 AM

$ACTU MAKING MOVES! Actuate Therapeutics just dropped topline Phase 2 results that could shake things up in metastatic pancreatic cancer 👇 🧪 The new drug combo helped patients live about 10 months, compared to just 7 months with the usual treatment — that’s a 3-month boost in survival, which is a big deal in cancer care. https://chartingdaily.com/the-future-of-oncology ✅ Statistically significant improvement ✅ Well-tolerated safety profile Communicated Disclaimer: This is not financial advice. please continue your DD and learn more about this company! $CAPR $ANAB $PCRX

0 · Reply

50bps Jun. 1 at 6:11 PM

$PCRX

0 · Reply

Night_Owl_Biotech May. 24 at 5:05 PM

FY2028 (Year 4) revenue multiples of all commercial-stage non-oncology focused bios (new since 1/1/2017) sorted low to high. 2 recent peer M&A transactions were at 5.5X FY2028 projected revenues (ITCI) and 2.6X (SWTX). $ARDX trades at the lowest FY28 multiple in this peer group but has patents expiring in FY34 so it may not be relevant but still... Others trading @ lower FY28 multiples include $PCRX $TVTX (which is down 20%+ the last week or two after the FDA accepted a filing). $ACAD just scored a major patent extension & $BHVN has an active PDUFA (but is not technically commercial-stage). Read our earlier post for cumulative 10-Year projected revenue multiples. This is not investment advice. We are merely sharing one analysis of dozens needed to assess valuation potential.

0 · Reply

Hangalvan May. 20 at 2:02 PM

$PCRX

0 · Reply

50bps May. 15 at 7:50 PM

$PCRX 👀

0 · Reply

BobbyPeruJLTC May. 12 at 4:42 PM

$PCRX give me $30 dammit

0 · Reply

JarvisFlow May. 9 at 1:00 PM

Needham has updated their rating for Pacira BioSciences ( $PCRX ) to Buy with a price target of 30.

0 · Reply

lecorb May. 8 at 8:28 PM

$PCRX Pacira BioSciences Non-GAAP EPS of $0.62 beats by $0.02, revenue of $168.9M misses by $6.98M

0 · Reply

BobbyPeruJLTC May. 8 at 4:37 PM

$PCRX numbers will be great. Tomorrow 30 plus

0 · Reply

BobbyPeruJLTC May. 7 at 3:33 PM

$PCRX buyback instills confidence. great earnings tomorrow and upbeat guidance and we are on a roll

0 · Reply

Market Cap	1.11B
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
EPS (ttm)	N/A
PE Ratio	11.90
Forward PE	12.60
Profit Margin	-14.20%
Debt to Equity Ratio	0.40

Volume	866,000
Avg Vol	660,662
Day's Range	N/A - N/A
Shares Out	44.93M
Stochastic %K	84%
Beta	0.48
Analysts	Sell
Price Target	$30.60